Which Is the Better International ETF, Vanguard's VEA Targeting Developed Markets or Schwab's Emerging Market-Focused SCHE?

The article contrasts Vanguard’s VEA (developed markets) and Schwab’s SCHE (emerging markets): SCHE has a higher expense ratio (0.06% vs 0.03%) and a more concentrated tech exposure (~34% in technology) plus heavy regional focus (about 34% Taiwan and 26% China). Despite similar dividend yields (~2.5–2.6%), SCHE’s 1-year total return is lower (19.7% vs VEA’s 28.9%) and it shows higher 5-year max drawdown (-31.4% vs -29.7%), implying greater volatility. The key takeaway is that VEA is positioned as the lower-cost, more diversified “buy-and-hold” option, while SCHE is for investors seeking higher-growth emerging-market exposure and accepting country/sector risk.

Analysis

The real signal is not the fee gap; it is the factor stack hidden inside each wrapper. SCHE is effectively a high-conviction Taiwan/China tech trade dressed up as diversification, so it should move with AI capex cycles, semis inventory turns, and any escalation in U.S.-China policy risk. That makes TSM the cleanest fundamental beneficiary, while BABA and TCEHY remain hostage to multiple compression unless there is durable policy support and a broadening of earnings revisions.

VEA is the more usable institutional allocation because liquidity and breadth matter more than 3 bps of expense ratio. In a risk-off quarter, its lower beta and broader developed-market mix should hold up better than SCHE; in a weaker-dollar environment it also has more room to benefit from Europe/Japan earnings translation. The hidden loser is any investor using SCHE as a proxy for EM growth: the concentration means they are taking a semis-plus-China policy bet, not a clean GDP-growth bet.

Contrarian view: the market is probably overemphasizing cost and underweighting concentration risk. The apparent lower volatility in SCHE is fragile; if geopolitics or tariff headlines hit Taiwan, correlations will spike and the diversification benefit vanishes. Conversely, if China stimulus genuinely turns into upward EPS revisions, SCHE could rerate hard and the current skepticism would be the wrong trade to fight.

Key Decisions for Investors

• No immediate directional trade in VEA vs SCHE; keep it on watch until there is a clearer catalyst in USD, China policy, or global earnings revisions.
• If forced into a 1-3 month relative-value position, long VEA / short SCHE in equal dollars; target 3-5% spread outperformance for VEA in a risk-off tape, with a stop if MSCI EM revisions turn up materially.
• Prefer single-name semis over ETF exposure: long TSM or ASML vs owning SCHE, to isolate AI capex upside while stripping out China-policy and broad EM beta.
• If holding SCHE, hedge the China internet sleeve with underweights or puts on BABA and TCEHY; this pair only works if policy stimulus does not translate into sustained multiple expansion.